Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments
Current Oncology · 19.03.2026 · 33 (3) · 174
DOI: 10.3390/curroncol33030174 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Current Oncology, online erschienen am 19.03.2026. Verfasst von Julie Patenaude und 6 weiteren Autor:innen. Beteiligte Einrichtung: PeriPharm Inc., 420 Notre-Dame Ouest, Suite 501, Montreal, QC H2Y 1V3, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Quality of Life, Caregivers. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Myeloma Canada, AbbVie Corporation.
Abstract (Originalsprache)
Background
Validated patient- and caregiver-reported outcome (PRO and CRO) questionnaires are widely used to assess quality of life (QoL) in multiple myeloma (MM). However, most were developed before recent therapeutic advances that have modified disease trajectories and may no longer fully reflect patients’ and caregivers’ experiences.
Methods
A Canadian cross-sectional observational study was conducted in collaboration with the PROxy Network and Myeloma Canada. Patients with MM completed the EORTC QLQ-C30, EORTC QLQ-MY20, EQ-5D-5L, and ESAS-R questionnaires and caregivers of patients with MM completed the CarGOQoL. Both groups rated their perceived QoL using a numerical rating scale. The strength of associations between validated questionnaire global scores and self-perceived QoL was assessed using Spearman’s correlation coefficient (r).
Results
Between October 2024 and February 2025, the study enrolled 305 patients and 104 caregivers. Moderate correlations were observed between patients’ perceived QoL and validated PRO global scores (range of r: 0.59 to 0.65). The MM-specific QLQ-MY20 showed one of the lowest correlations (r = 0.59; 95% confidence interval (CI) 0.51–0.66; p < 0.001). The caregiver-reported CarGOQoL also demonstrated a moderate association (r = 0.54; 95% CI 0.38–0.67; p < 0.001).
Conclusions
Contemporary treatment advances, including prolonged survival and evolving side effect profiles, may not be reflected in currently available PRO and CRO instruments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PeriPharm Inc., 420 Notre-Dame Ouest, Suite 501, Montreal, QC H2Y 1V3, Canada.
- Myeloma Canada, 1255 TransCanada, Suite 160, Dorval, QC H9P 2V4, Canada.
ORCID-Profile: Ariane Légaré, Catherine Beauchemin, Jean Lachaine
Förderung
- Myeloma Canada
- AbbVie Corporation
Zitieren
APA
Patenaude, J., Légaré, A., Dupont, F., Colasurdo, G., Elias, M., Beauchemin, C., & Lachaine, J. (2026). Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments. Current Oncology, 33(3), 174. https://doi.org/10.3390/curroncol33030174
Vancouver
Patenaude J, Légaré A, Dupont F, Colasurdo G, Elias M, Beauchemin C, et al. Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments. Current Oncology. 2026;33(3):174. doi:10.3390/curroncol33030174
BibTeX
@article{Patenaude2026,
author = {Patenaude, Julie and Légaré, Ariane and Dupont, Florence and Colasurdo, Gabriele and Elias, Martine and Beauchemin, Catherine and Lachaine, Jean},
title = {Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {3},
pages = {174},
doi = {10.3390/curroncol33030174}
}
EUVIMED